Survey on Epidemiology of Hypoparathyroidism in France

Study Overview
=================
Brief Summary
-----------------
Very few data has been published on the epidemiology of hypoparathyroidism worldwide: none exists specifically for France. Hypoparathyroidism could led to complications. Here, the investigators plan to collect data about both epidemiology, medication and complication of hypoparathyroidism in France.

Detailed Description
-----------------
Very few data has been published on the epidemiology of hypoparathyroidism worldwide. None exists specifically in France. Hypoparathyroidism could led to complications: e.g. symptomatic hypocalcemia, calcifications (brain, eye and other soft tissues), nephrolithiasis/nephrocalcinosis, renal insufficiency. Here,the investigators plan to collect data about both epidemiology, medication and complication of hypoparathyroidism in France.

Official Title
-----------------
Epi-Hypo: Survey on Epidemiology of Hypoparathyroidism in France

Conditions
-----------------
Hypoparathyroidism

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patient fro whom chronic hypoparathyroidism is diagnosed patient living in France Exclusion Criteria: patient who does not want his data to be collected in this registry pseudo-hypoparathyroidism acute hypoparathyroidism
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Hypoparathyroidism<br>No intervention. | Other: No intervention<br>* No intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of the epidemiology of patients with hypoparathyroidism in France | Data collected by questionnaire about etiology of hypoparathyroidism, filled by physicians from clinic folders | Through study completion, about 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of the biology at inclusion will describe the evolution of the included population from diagnosis to now (inclusion) | Number of patients with at least one anomaly at biology (calcemia in mM, calciuria in mmol/j, parathormone in pg/ml, creatininemia in µM, phosphatemia in mM, vitamin D in nmol/l & magnesemia in mM) at inclusion | At inclusion (under treatment): through study completion, about 2 years | 
| Assessment of the management at inclusion will describe treatment and complications at inclusion | Number of patients with clinical outcomes (complications such as cataract, nephrolithiasis, nephrocalcinosis, and others) and their management at inclusion | At inclusion (under treatment): through study completion, about 2 years | 
| Assessment of the biology (calcemia, calciuria, parathormone, creatininemia, phosphatemia & magnesemia) at diagnosis and drug therapy at inclusion will describe population | Number of patients with at least one anomaly at biology (calcemia in mM, calciuria in mmol/j, parathormone in pg/ml, creatininemia in µM, phosphatemia in mM, vitamin D in nmol/l & magnesemia in mM) at diagnosis | Through study completion, about 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hypoparathyroidism, Epidemiology, Medication Therapy Management